Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and cis-platinum (II) diaminedichloride (NSC 119875)

Ellerby, Richard A.; Davis, Hugh L.; Ansfield, Fred J.; Ramírez, Guillermo

doi:10.1002/1097-0142(197410)34:4<1005::aid-cncr2820340407>3.0.co;2-k

Cited by 20 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent advances with implantable drug delivery systems have enabled the repeated arterial infusion of chemotherapeutic agents in patients with HCC. Effective combination regimens established on the basis of biochemical modulation have achieved a significantly improved survival benefit for patients with advanced HCC 16,. Ando et al1 reported a relatively high response rate (44%) with HAIC with CDDP and 5‐FU.…”

Section: Discussionmentioning

confidence: 99%

“…Effective combination regimens established on the basis of biochemical modulation have achieved a significantly improved survival benefit for patients with advanced HCC. 16,[28][29][30] Ando et al 1 reported a relatively high response rate (44%) with HAIC with CDDP and 5-FU. Two of their nine patients with mPVTT demonstrated complete responses with recanalization of the portal trunk.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study

Niguma

Mimura

Tutui

2005

J Hepatobiliary Pancreat Surg

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study

Niguma

Mimura

Tutui

2005

J Hepatobiliary Pancreat Surg

View full text Add to dashboard Cite

show abstract

“…Ototoxicity has been reported more commonly in human patients than in the dog, likely because of our inability to determine this clinical change consistently in the latter species. Ototoxicity has been observed in 7–90% of human patients receiving doses of up to 120 mg m −2 per course 110,111 . Hearing loss is in the high‐frequency range and is dose related, cumulative and frequently irreversible 112,113 .…”

Section: Toxicitiesmentioning

confidence: 99%

Cisplatin: a review of toxicities and therapeutic applications

Barabas

Milner

Lurie

et al. 2008

Vet Comparative Oncology

389

261

View full text Add to dashboard Cite

Cisplatin is a platinum chemotherapeutic used in a variety of malignancies. The antineoplastic activity occurs from DNA cross-links and adducts, in addition to the generation of superoxide radicals. Nephrotoxicity is the most well-known and potentially most clinically significant toxicity. Unfortunately, the mechanism for cisplatin nephrotoxicity has not been completely elucidated; however, many theories have been developed. Other toxicities include gastrointestinal, myelosuppression, ototoxicity and neurotoxicity. Saline diuresis is currently the most accepted way to prevent cisplatin nephrotoxicity. Research has focused on pharmaceuticals and enzyme/molecular alterations as alternatives to long-term diuresis. No agents have currently been identified that can protect from all toxicities. Cisplatin has shown activity against osteosarcoma, transitional cell carcinoma, squamous cell carcinoma (SCC), melanoma, mesothelioma, carcinomatosis and germinal cell tumours in the dog. In the cat, cisplatin cannot be utilized because of fulminant pulmonary oedema that occurs at standard doses. Intralesional cisplatin has been utilized in horses for the treatment of SCC and sarcoids.

show abstract

“…Since the, FUraI has been used in a variety of clinical trials, usually in combination with other drugs [21]. As an infusion this drug was combined by our group in 1980 with a new active agent, cisplatinum.…”

Section: Introductionmentioning

confidence: 99%

The clinical syndrome of 5-fluorouracil cardiotoxicity

et al. 1989

View full text Add to dashboard Cite

5-fluorouracil (FUra) is one of the most frequently used drugs in cancer treatment, particularly in combination with other agents. Its activity when administered as an infusion rather than a bolus has led to a renewed and increased use. A cardiotoxicity that mimics ischemia has been associated with the administration of FUra in cancer patients. This cardiotoxicity may manifest itself as: (a) dysrythmias with and without cardiorespiratory symptoms (b) ECG changes with and without cardiorespiratory symptoms (c) cardiorespiratory symptoms with and without ECG changes (d) acute myocardial infarct; symptoms and ECG changes (e) ventricular dysfunction (f) cardiogenic shock and (g) sudden death. Several case studies which illustrate the cardiotoxic sequelae that may be associated with the use of this drug are discussed. The incidence, contributing factors, risk factors and mechanisms underlying this phenomenon are undetermined. No appropriate recommendations for monitoring patients or for predicting those patients that will develop such toxicity while receiving FUra can be made at present. Prospective studies to determine the true incidence, spectrum and mechanisms causing this syndrome are ongoing and required for its understanding and prevention.

show abstract

Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and cis-platinum (II) diaminedichloride (NSC 119875)

Cited by 20 publications

References 10 publications

Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study

Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study

Cisplatin: a review of toxicities and therapeutic applications

The clinical syndrome of 5-fluorouracil cardiotoxicity

Contact Info

Product

Resources

About